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Summary
Approximately 0.5%–1% of the general population has
been estimated to be heterozygous for a germline mu-
tation in the ATM gene. Mutations in the ATM gene are
responsible for the autosomal recessive disorder ataxia-
telangiectasia (A-T) (MIM 208900). The finding that
ATM-heterozygotes have an increased relative risk for
breast cancer was supported by some studies but not
confirmed by others. In view of this discrepancy, we
examined the frequency of ATM germline mutations in
a selected group of Dutch patients with breast cancer.
We have analyzed ATM germline mutations in normal
blood lymphocytes, using the protein-truncation test fol-
lowed by genomic-sequence analysis. A high percentage
of ATM germline mutations was demonstrated among
patients with sporadic breast cancer. The 82 patients
included in this study had developed breast cancer at
age !45 and had survived 5 years (mean 15 years),
and in 33 (40%) of the patients a contralateral breast
tumor had been diagnosed. Among these patients we
identified seven (8.5%) ATM germline mutations, of
which five are distinct. One splice-site mutation (IVS10-
6TrG) was detected three times in our series. Four het-
erozygous carriers were patients with bilateral breast
cancer. Our results indicate that the mutations identified
in this study are “A-T disease–causing” mutations that
might be associated with an increased risk of breast can-
cer in heterozygotes. We conclude that ATM heterozy-
gotes have an approximately ninefold-increased risk of
developing a type of breast cancer characterized by fre-
quent bilateral occurrence, early age at onset, and long-
term survival. The specific characteristics of our popu-
lation of patients may explain why such a high frequency
was not found in other series.
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Introduction
Individuals with the autosomal recessive disorder ataxia-
telangiectasia (A-T) (MIM 208900) are homozygous or
compound heterozygous for a mutation in theATM gene
(Savitsky et al. 1995; Lavin and Shiloh 1997). More than
300 different disease-causing mutations, located
throughout this gene’s open reading frame (ORF), have
been identified thus far. The disease has an estimated
incidence of 1/40,000–1/100,000 live births and is char-
acterized by several clinical features—for example, cer-
ebellar ataxia, dilated blood vessels in the eyes and skin
(telangiectasia), immune deficiency, chromosomal insta-
bility, predisposition to cancer, and increased sensitivity
to ionizing radiation (Gatti et al. 1991; Segdwick and
Boder 1991; Shiloh 1995; Lavin and Shiloh 1996, 1997).
The typical phenotype is caused by ATM null alleles that
either truncate (frameshift or stop-codon mutations) or
severely destabilize (mutations affecting mRNA splicing)
the ATM protein (Gilad et al. 1998; Sandoval et al.
1999; Teraoka et al. 1999).
A number of epidemiological studies have indicated
that female ATM-heterozygous carriers have an excess
risk of breast cancer, with an estimated relative risk of
3.9 (95% confidence interval [CI] 2.0–6.0) (Swift et al.
1987, 1991; reviewed in Easton 1994; Inskip et al. 1999;
Janin et al. 1999). Several recent studies have been con-
ducted to verify this hypothesis. Athma et al.’s (1996)
study of families with A-T showed that female ATM-
mutation carriers have an increased relative risk for
breast cancer: 3.8. In spite of that, studies of patients
with breast cancer have so far failed to confirm the find-
ings in families with A-T. Fitzgerald et al. (1997), ana-
lyzing a series of young patients with breast cancer, sug-
gested that ATM-heterozygous germline mutations do
not contribute to early-onset (age !40 years) sporadic
breast cancer. Moreover, in a third recent report, Chen
et al. (1998) conclude that the contribution of hetero-
zygous ATM mutations to familial breast cancer is
minimal.
In the present study we examined whetherATM germ-
line mutations can be found in a selected group of Dutch
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patients with breast cancer. We determined the ATM
mutation frequency in women who had developed breast
cancer at a young age. Using the protein-truncation test
(PTT) as the mutation-detection method, which was fol-
lowed by genomic sequencing, we expected to have a
mutation-detection sensitivity of ∼75% (Broeks et al.
1998). We had reported elsewhere that there was no
common ATM founder mutation present in a small series
of 12 Dutch patients with A-T and that the mutations
had been found throughout the ORF of the ATM gene,
with no apparent hotspots.
Subjects and Methods
Study Population
The patients in this study were selected from a large
cohort of patients with breast cancer who had been
treated at either The Netherlands Cancer Institute (Am-
sterdam) or The Dr. Daniel den Hoed Cancer Center
(Rotterdam), during 1970–90. Patients with contralat-
eral breast cancer ( ) were eligible if their firstn = 33
breast cancer had been diagnosed at age !45 and 5
years before the diagnosis of contralateral disease. Pa-
tients with unilateral disease ( ) also had to haven = 49
been diagnosed with breast cancer at age !45 and had
to have survived 5 years without developing contra-
lateral disease. On the basis of their birth names, all 82
patients were inferred to be of Dutch ethnic origin. In-
formation regarding a family history of breast cancer
was obtained by means of a questionnaire mailed to all
patients. The extent of family history of breast cancer
was divided into three categories (one case–i.e., the index
case—had to be diagnosed at age !45, paternal inheri-
tance was considered to be first degree): (1) heredi-
tary—three family members with breast cancer in two
generations, who were first-degree relatives of each
other; (2) sporadic—either a single breast cancer case or
only one second-degree relative with breast cancer; and
(3) familial—all others. Each of these patients was asked
to donate a 20-ml blood sample for DNA and RNA
isolation, and informed consent was obtained. To de-
termine the frequency of specific ATM mutations in the
Dutch population, DNA samples from 268 healthy in-
dividuals of Dutch ethnic origin (179 males and 89 fe-
males of which 51 were age !45 years) were obtained
from the Blood Bank at Leiden.
Generation of Genomic DNA and Total RNA and
Preparation of cDNA
Peripheral blood lymphocytes were used to isolate ge-
nomic DNA and total RNA, with DNAzol (Gibco) and
RNAzol B (Ampro) methods, respectively, according to
the manufacturers’ protocol. A 25–1.25-mg sample of
total RNA was used in the cDNA reaction, which was
conducted by means of a Superscript II kit, according
to the manufacturer’s (Gibco BRL) protocol.
PTT
The ATM ORF was divided into 10 overlapping frag-
ments of ∼1–2 kb each, with an overlap of 400–500 bp
to avoid the possibility that truncations close to the ends
of the fragments could be missed. Forward primers all
include a T7-promoter sequence for the transcriptional
initiation of T7 RNA polymerase and an ATG codon
for translational initiation. Nested PCR was necessary
only for amplification of region I. Primer sequences are
available on request.
The PCR of each region was performed in a total
volume of 30 ml containing 1 ml of cDNA template, 3
ml PCR buffer 6 (Stratagene), 0.2 mM of each dNTP,
15 pmol of each (forward and reverse) primer, 1.5 ml of
dimethyl sulfoxide, 1 unit of Taq DNA-polymerase
(Gibco BRL), and 0.25 units of PWO DNA-polymerase
(Boehringer). The PCR regions were amplified in a
PTC200 apparatus (MJ Research) for 1 min at 94C (for
denaturing); 35 cycles of 10 s at 92C, 1 s at 70C (with
a decrease of 0.5C/s until 55C was attained), 10 s at
55C (with an increase of 0.7C/s until 72C was at-
tained), 2.5 min at 72C; and, finally, 5 min at 72C.
The outer PCR of region I was performed in 15 cycles
in a total volume of 30 ml, under the same conditions
as described above, and 1 ml of the product of the first
PCR was used for the nested inner PCR. PCR products
were analyzed by agarose gel-electrophoresis.
From each sample, 2 ml of PCR product was used for
the in vitro transcription-translation reaction using the
TNT T7 Coupled Reticulocyte Lysate System (L4610;
Promega). The reaction was performed according to pro-
tocol in a 6.25-ml total volume containing 2 ml of PCR
product, 3.1 ml of rabbit reticulocyte lysate, 0.25 ml of
TNT-buffer, 0.125 ml of amino acid mixture (minus me-
thionine), 0.5 ml of [35S]-methionine (10 mCi/ml), 0.125
ml (40 units/ml) of RNAse inhibitor, and 0.125 ml of T7
RNA polymerase. The reaction mixture was incubated
for 60 min at 30C. The translation products were sep-
arated on a 15% SDS-polyacrylamide gel, and the gels
were fixed, incubated in fluorographic reagent (Amplify;
Amersham), dried, and subjected to autoradiography.
Each gel contained a 14C-labeled high-molecular-weight
rainbow marker (Amersham) as a size standard.
Nucleotide-Sequence Analysis
All aberrant PTT patterns were analyzed by sequence
analysis, first on cDNA and finally on genomic DNA,
to identify candidate mutations. Sequence analysis was
performed by means of the “DNA Sequencing Kit” big-
dye primer cycle sequencing ready reaction with 21M13
and M13 reverse primers (PE Biosystems). Sequencing
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Table 1
Frequency of All ATM Germline Mutations and of the ATM
IVS10-6TrG Splice-site Mutation in Patients and Controls
Group
All ATM
Mutations
ATM
IVS10-6TrG
Breast cancer at age !45 years:
Unilateral 3/49 2/49
Bilateral 4/33 1/33
Total 7/82 (8.5%) 3/82 (3.7%)
Controls .5%–1.0%a 2/268 (.7%)
a Data are from the literature.
products were analyzed with the ABI 377 automated
sequencing apparatus and corresponding software.
IVS10-6TrG Mutation–Specific Assay
A 100- ng sample of genomic DNA was amplified, in
a total volume of 30 ml containing 3 ml of PCR buffer
with 3 mM MgCl2, 15 pmol of each primer, an intron
10 forward primer (IVS10-146: 5′-ctg agg cag gag aat
cac ttg) and an exon 11 reverse primer (nucleotide 1213:
5′-tct gtg act tct gaa ggt gat c), 0.7 ml of AmpliTaq gold,
and 3 ml (2 mM each) of each dNTP, in the PTC200
(MJ research) apparatus, for 6 min at 94C; 20 cycles
of 30 s at 94C, 20 s at 65C (with a decrease of 0.5C/
s/cycle until 55C was attained), 2.5 min at 72C, fol-
lowed by 20 cycles annealing at 55C; and, finally, 5 s
at 72C). PCR fragments were digested with 5 units of
RsaI for 2 h at 37C and were analysed on a 2% agarose
gel.
IVS10-6TrG Splicing
PCR with forward primer FSQ1 (nucleotide 2: 5′-
gtg tgt tct gaa att gtg aac) and reverse primer RSQ2
(nucleotide 1370: 5′-cgt aac aca tat ggt gta cg) resulted
in two fragments—one including exon 11 and the other
excluding it—of 1,373 and 1,203 bp, respectively. These
products were separated on a 1.2% agarose gel and were
isolated from gel. The products were individually se-
quenced, and a polymorphism at nucleotide position 37,
37C/T, was used as an allele-specific marker; nucleotide
37C is linked to the normal sequence IVS10-6T, whereas
nucleotide 37T is linked to the mutation IVS10-6G.
Tumor-Tissue Histology and Immunohistochemistry
For each paraffin-embedded tumor, six 10-mm paraffin
slides were used for genomic-DNA isolation (whereas
three 10-mm paraffin slides are used in the standard pro-
tocol [Sambrook et al. 1989]), and an hematoxylin-eo-
sin–stained slide was used for histopathological
examination.
Loss of Heterozygosity (LOH)
LOH of the microsatellite marker D11S2179 (located
in ATM) in tumor material was determined by compar-
ison of peak-height ratios of normal tissue with those
of tumor tissue. The peak height of the longer allele peak
was divided by the peak height of the shorter allele peak.
The ratio obtained in the tumor DNA was divided by
the ratio obtained in normal-tissue DNA. LOH was de-
termined by ratios 12 or !0.5, depending on which allele
was lost. Microsatellite analysis was performed by PCR
in a total volume of 30 ml containing 5–10 ng of genomic
DNA, 3 ml PCR buffer 6 (Stratagene), 0.2 mM of each
dNTP, 9 pmol of each primer (listed in The Genome
Database), and 1.5 units of Taq polymerase, in a mul-
ticycler PTC200 apparatus (MJ Research). The PCR
products were amplified in 30 cycles of 30 s for 94C,
1 min at 62C, and 1 min at 72C; were electrophoresed
on an ABI 373 or 377 automated sequencing apparatus;
and were analysed by means of GENESCAN 2.1. Sub-
sequently, sequence analysis of the tumor DNA was used
to determine whether the wild-type or mutant allele was
lost.
Results
Seven ATM Germline Mutations in 82 Selected
Patients with Breast Cancer
Among 82 patients with sporadic breast cancer, we
have identified in 7 (8.5%) ATM germline mutations, of
which five are distinct (tables 1 and 2); these mutations
either already had been described as A-T disease causing
mutations elsewhere (Ataxia-Telangiectasia Mutation
Database; T. Do¨rk, personal communication), as causing
the disease in patients with A-T or are truncating mu-
tations (table 2; patients ATMb56 and ATMb73) and
therefore most likely are pathological mutations.
All patients with breast cancer who were included in
our study were diagnosed with breast cancer at age !45
and had survived for 5 years after diagnosis (mean du-
ration of follow-up was 15 years), and in 33 (40%) of
these patients a contralateral breast tumor was diag-
nosed 5 years after the first diagnosis of breast cancer.
The proportion of women in the ATM-mutated group
who had hereditary or familial versus sporadic breast
cancer were roughly similar to those in the group of
women who did not have an ATM germline mutation
(table 3A). Additional characteristics of these patients
and their tumors are listed in table 3. Patients with an
ATM germline mutation were slightly older at the first
diagnosis of their first breast cancer and had a slightly
longer follow-up period, and a higher proportion of
them had bilateral disease (tables 1 and 3A). However,
none of these differences was statistically significant,
possibly because of the small number of patients. Fur-
thermore, no specific clinicopathological characteristics
(e.g., histology or tumor stage) of ATM-heterozygous
patients were apparent (table 3B).
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Table 2
Seven ATM Germline Mutations in Patients With Breast Cancer at Age !45 Years
Patient Genomic Mutationa Predicted Alteration in ATM Proteinb
Bilateral breast cancer:
ATMb56 3114ArT (exon 23) Stop codon, truncation at amino acid 1039
ATMb57 IVS10-6TrG (exon 11) Out-of-frame deletion, truncation at amino acid 419
ATMb58 IVS142TrG (exon 14) In-frame deletion codons 601-633
Unilateral breast cancer:
ATMb73 1660delA (exon 13) Truncation at amino acid 555
ATMc211 1562delAG (exon 12) Truncation at amino acid 564
ATMc214 IVS10-6TrG (exon 11) Out-of-frame deletion, truncation at amino acid 419
ATMc232 IVS10-6TrG (exon 11) Out-of-frame deletion, truncation at amino acid 419
a Nucleotide positions indicated are numbered in accordance with reference sequence ATG = 1 (Platzer et
al. 1997).
b Length is 3,056 amino acids.
ATM Germline Mutation IVS10-6TrG
The splice-site mutation IVS10-6TrG, localized in the
highly conserved pyrimidine tract of the 3′ splice-accep-
tor site of intron 10, was detected in three unrelated
patients with breast cancer in this study (3.7% of the
sample; see table 1). We assessed the frequency of this
particular mutation in the general population, using a
mutation-specific assay (see the Subjects and Methods
section). In the general population, we detected this mu-
tation in 2 (both males) of 268 healthy controls, which
results in an estimated frequency of ∼0.7% (95% CI
0%–1.7%) for this mutation alone. Haplotype analysis
of the five individuals with this mutation, using seven
microsatellite markers located in the ATM region (Laake
et al. 1999), revealed that the ATM IVS10-6TrG mu-
tation is present on at least two different alleles, each
sharing a different set of at least three of these seven
markers (authors’ unpublished observations).
The IVS10-6TrG mutation leads to incorrect splicing
of exon 11 and to exon skipping, resulting in a frame-
shift and subsequent truncation of the protein at amino
acid residue 419. Assaying for a mutation-linked poly-
morphism at nucleotide position 37, we determined that
a small proportion (!10%) of the mutant allele is spliced
correctly, resulting in some full-length mRNA (data not
shown). The wild-type allele did not display any incor-
rect splicing.
LOH: Not a Prerequisite for Initiation of Breast Cancer
in ATM Heterozygotes
To obtain further insight into the precise role of ATM
in tumorigenesis in ATM-heterozygous patients, we in-
vestigated whether the loss of the wild-type ATM allele
in these tumors was a prerequisite for tumor develop-
ment. We analyzed LOH of the ATM locus—that is,
chromosomal region 11q22-23—in four breast tumors
in three ATM heterozygotes, using the microsatellite
marker D11S2179, located within the ATM gene. One
patient (ATMb56) with bilateral breast cancer showed
LOH in the first tumor (data not shown); however, se-
quence analysis revealed that it was the mutant allele
that was lost in the tumor—in, remarkably, only a pro-
portion (∼50%) of the tumor cells. Two other infor-
mative tumors, one each in patients ATMb57 and
ATMb58, showed no LOH.
Discussion
We have identified a high percentage of ATM germline
mutations among selected patients with breast cancer.
The mutations that are described in this study are most
likely ATM null alleles, since most of them either trun-
cate the ATM protein or have been described, elsewhere
(Ataxia-Telangiectasia Mutation Database; T. Do¨rk, per-
sonal communication), as occurring in patients who are
homozygous or compound heterozygous for A-T. Our
results do not show an overrepresentation of hereditary
breast cancer among patients with breast cancer and
heterozygous ATM germline mutations, thereby exclud-
ing the likelihood of the presence of a breast can-
cer–susceptibility gene, such as BRCA1 or BRCA2, that
would account for predisposition to breast cancer.
One mutation, the exon 11 splice-site mutation
IVS10-6TrG, was found frequently among the patients
with breast cancer in this study (frequency 3.7%, vs.
0.7% in the general population). Despite this high fre-
quency in the Dutch population, the IVS10-6TrG mu-
tation has not been detected thus far in a small series of
Dutch patients with A-T (Broeks et al. 1998). However,
a patient with A-T who was homozygous for the exon
11 splice-site mutation has been identified in Germany
(T. Do¨rk, personal communication). Our data suggest
that this particular ATM mutation might be associated
with an increased risk of breast cancer in ATM
heterozygotes.
None of the tumors of the ATM heterozygotes tested
for LOH showed LOH of the wild-type allele. Thus, it
seems that a mutant ATM germline allele plays a role
in tumor initiation but that complete loss of the normal
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Table 3
Patient and Histopathological Characteristics of All Patients with Breast Cancer and of ATM Heterozygotes
A. All Patients with Breast Cancer
Characteristic
Patients without ATM
Mutation ( )n = 75
Patients with ATM
Mutation ( )n = 7
Mean age [range] at diagnosis (years):
First breast cancer 38.0 (22.1–45.0) 40.5 (35.7–43.3)
Second breast cancer ( )n = 33 46.3 (27.3–55.7) 50.6 (43.7–59.3)
Interval [range] between diagnosis of first tumor and diagnosis of second tumor (years) 9.9 (4.6–19.9) 11.0 (6.8–19.6)
Mean follow-up period [range] since diagnosis (years):
First tumor 15.0 (7.5–25.7) 16.8 (13.9–24.1)
Second tumor ( ])n = 33 5.3 (.7–16.8) 6.4 (4.4–8.4)
Type of breast cancer in family:a
Hereditary 10% 14%
Familial 16% 14%
Sporadic 74% 72%
B. ATM Heterozygotes
Patient (Mutation) and
Diagnosis of Breast Cancer
Age
(years) Histology TNM Stage
Interval
(years)
Follow-Up
Period since
First Diagnosis
of Breast Cancer
ATMb56 (3114ArT):
First diagnosis 40 Ductal carcinoma in situ T0N0M0 14.3
Second diagnosis 46 Infiltrating ductal carcinoma/ductal carcinoma in situ T2N1M0 6.8
ATMb57 (IVS10-6TrG):
First diagnosis 39 Ductal/lobular carcinoma in situ T0N0M0 24.1
Second diagnosis 59 Ductal carcinoma in situ T0N0M0 19.6
ATMb58 (IVS142TrG):
First diagnosis 35 Infiltrating ductal carcinoma T1N0M0 16.4
Second diagnosis 43 Infiltrating ductal carcinoma T2N0M0 8
ATMb73 (1660delA):
First diagnosis 42 Infiltrating ductal carcinoma T2N1M0 14.8
Second diagnosis 52 Infiltrating ductal carcinoma T1N0M0 9.7
ATMc211 (1562delAG):
First diagnosis 39 Infiltrating lobular carcinoma T1N0M0 17.8
ATMc214 (IVS10-6TrG):
First diagnosis 43 Infiltrating ductal carcinoma T1N1M0 13.9
ATMc232 (IVS10-6TrG):
First diagnosis 42 Infiltrating ductal carcinoma T2NxM0 16.2
a For category descriptions, see the Subjects and Methods section. Data were available for 7 mutation carriers and for 70 non– mutation
carriers.
protein is not a prerequisite for tumor initiation. Loss
of the mutant allele, as was found in patient ATMb56,
could be explained by LOH directed by a locus in close
proximity to ATM, which would be important at a later
stage during tumor development (Laake et al. 1997,
1999).
Our results support the hypothesis that ATM heter-
ozygotes do have an increased risk of development of
breast cancer. The specific characteristics of our the pa-
tients whom we studied (i.e., early age at onset, frequent
occurrence of contralateral disease, and long-term sur-
vival) may explain why such a high frequency of ATM
germline mutations was not found in other studies of
patients with breast cancer (Fitzgerald et al. 1997; Chen
et al. 1998). For a precise assessment of their risk, data
are needed on the prevalence of ATM-heterozygous mu-
tations in a large group of women without breast cancer.
In the absence of such data, we have used the commonly
accepted upper estimate of 1% heterozygotes in the
Dutch population (based on an upper estimate of 1/
40,000 A-T live births in The Netherlands; Jaspers, per-
sonal communication) to estimate that ATM heterozy-
gotes have an approximately ninefold-increased risk,
compared with nonheterozygotes, of developing a breast
tumor with specific characteristics (early age at onset,
increased risk of contralateral disease, and long-term
survival).
It is well known that A-T is associated with high sen-
sitivity to ionizing radiation and that fibroblast strains
or cultures from ATM heterozygotes display moderate
levels of radiation sensitivity; on average, they are more
sensitive than are normal controls (Paterson et al. 1979;
West et al. 1995). All patients with breast cancer who
were included in the present study received low- dosage
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diagnostic radiation at a young age, as part of a screen-
ing program for tuberculosis. Moreover, all these pa-
tients had received radiation treatment for their first
breast tumor, and a nonsignificant trend toward a higher
incidence of ATM mutations was noted in women with
bilateral breast cancer. Thus, radiation might indeed be
an induction trigger for development of breast cancer in
ATM heterozygotes, and these data strongly suggest that
the role of ATM heterozygosity in the pathogenesis of
radiogenic cancers needs further investigation. Although
our findings indicate an approximately ninefold-in-
creased risk of heterozygous ATM mutation carriers for
breast cancer, we did not observe an extended family
history of breast cancer in these patients. However, since
an induction trigger might be a prerequisite for tumor
development, their relatives might not have been ex-
posed to such an environmental factor, as has been sug-
gested as well by a study of the incidence of breast cancer
in female relatives with A-T (Swift et al. 1991 Inskip et
al. 1999). We hope that in the near future we can provide
more insight into the quantitative contribution of ATM
heterozygosity to the risk of radiation-related cancers.
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